About

OUR MISSION

2N Pharma was founded in 2019 to build on a decade of research undertaken by our co-founder and CSO Dr. John Nieland and his associates. While the challenge ahead is immense, our aim is clear: we want to cure ALS.

We make this bold statement well knowing that brilliant scientists have had very limited success in developing disease modifying drugs, despite many decades of research. But we believe our novel approach to treating neurological disorders will be the departure from conventional neuroscience that is required to finally make significant progress towards a cure for ALS.

Board of Directors

Alex Leech

Chair

Alex Leech was the founding CEO of Alchemab Therapeutics and raised a £60m ($82m) Series A in 2021. He is a serial biotech CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and was CEO of Zarodex Therapeutics and Camphos Therapeutics. Prior to Creabilis, he led operations at US-based pain company Solace Pharmaceuticals Inc. Alex gained his R&D experience at Pfizer and is a former Venture Partner with SV Health Investors.

John Kemp, PhD

Director

John Kemp is currently the CSO of Syndesi Therapeutics. Former roles include Head of Neuroscience Discovery at Janssen, Belgium, and CEO of Evotec Neurosciences, which was spun-out from Evotec and raised a €25m Series A in 2004. Before joining Evotec, John was SVP and Head of CNS Research at Roche and he also held senior research positions in Neuroscience R&D at Merck Sharpe and Dohme. John has published over 140 peer reviewed articles, was an original member of ISI’s Most Highly Cited Researcher Database, and has an h-index of 74.

John Nieland, PhD

Director

John is 2N Pharma’s co-founder and CSO and brings broad management experience and in-depth research background. He was previously director of research at Medigene AG and is co-founder of the clinical-stage vaccine company 2A Pharma and two other biotech companies. In addition to his duties at 2N Pharma, John is also Associate Professor and Head of the Molecular Pharmacology Department at Aalborg University, Denmark.

Preben Bruun-Nyzell

Director

Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical-stage vaccine company 2A Pharma, and chairman of Apoglyx, a Swedish biotech focused on aquaporins. Earlier in his career, he worked for Roche in Basel and PwC in London. Previously, Preben was CFO of a company in the Middle East with 1,200 employees and sales of $1bn.

Giles Dudley, PhD

Board Observer

Giles Dudley is a Portfolio Manager at the BioInnovation Institute in Copenhagen and non-voting board observer. He has more than 10 years experience with fundraising, business development, market due diligence and IP development in biotech startups. Giles has a PhD in virology and previously worked with Sunergos Innovations, Edinburgh Bioquarter and several seed stage healthcare companies.

Team Members

Preben Bruun-Nyzell

CEO and Co-Founder

Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical-stage vaccine company 2A Pharma, and chairman of Apoglyx, a Swedish biotech focused on aquaporins. Earlier in his career, he worked for Roche in Basel and PwC in London. Previously, Preben was CFO of a company in the Middle East with 1,200 employees and sales of $1bn.

John Nieland, PhD

CSO and Co-Founder

John is 2N Pharma’s co-founder and CSO and brings broad management experience and a strong scientific background. He was previously director of research at Medigene AG. Next, he is co-founder of the clinical-stage vaccine company 2A Pharma. In addition to his duties at 2N Pharma, John is also Associate Professor and Head of the Molecular Pharmacology Department at Aalborg University, Denmark.

Alasdair Naylor, PhD

Drug Discovery

Alasdair Naylor is a pharmacologist with over 30 years of experience. He gained his expertise at Pfizer and Solace Pharmaceuticals. More, he is the founder of a new start-up pain company, Sevenless Therapeutics. In addition to holding senior positions in these companies, Alasdair Naylor has consulted widely in the biotech and venture sector. He advised on target validation, translational research, and incorporating this knowledge into robust research plans for implementation. Alasdair has led multiple drug discovery and early clinical development teams. This has led to numerous positive proof of concepts in Urology, neuroscience, and inflammation. Further, he published 50+ scientific papers. Besides that, he is an author on Pfizer and Sevenless Therapeutics patents.

Gavin Kilpatrick, PhD

Drug Discovery/Neuroscience

Gavin Kilpatrick Ph.D. is a pharmacologist with over 30 years of experience in the biotechnology and pharmaceutical sectors. He has held senior management positions at GSK, CeNeS, Paion, Roche, and Takeda. Moreover, he was a founder of the biotechnology company TheraSci Ltd. Gavin is a Fellow of the British Pharmacological Society, has authored or co-authored more than 80 academic publications, and contributed to the discovery and development of three drugs that have reached the market, most recently, remimazolam.

Anne Skøttrup Mørkholt, PhD

Project Manager

Anne completed her doctorate at the Laboratory of Metabolism Modifying Medicine, Aalborg University. She researched the connection between dysfunction of the lipid metabolism and CNS diseases, including multiple sclerosis and depression.

Steinunn Sara Helgudóttir, Project Manager

Steinunn Sara Helgudóttir, PhD

Project Manager

Steinunn completed her doctorate at the Neurobiology Research and Drug Delivery Group at Aalborg University. She conducted research on targeted drug delivery through the blood-brain barrier.

Thomas Brimert, PhD

Head of Medicinal Chemistry

Co-founder of Red Glead Discovery – a pre-clinical drug discovery CRO. Thomas Brimert is a skilled organic and medicinal chemist with over 20 years of experience. After a post-doc at the University of Odense in Denmark, he joined AstraZeneca R&D Lund as a Senior Research Scientist (2000-2011). Since 2011 he has had leading roles at Red Glead Discovery. He has contributed to successful deliveries of clinical candidates both at AstraZeneca and Red Glead Discovery.

Advisors

Michael Sloth Trabjerg, MD, PhD

Scientific Advisor

Dr. Michael Sloth Trabjerg is a Medical Doctor and completed his PhD at the Laboratory of Metabolism Modifying Medicine, Aalborg University with research into CPT1 as a potential target to restore dysregulated metabolism in neurodegenerative diseases.

Angelique Corthals, MD, PhD

Scientific Advisor

Dr. Angelique Corthals is a biomedical researcher who has published on the connection between metabolic dysfunction and neurological disorders. She is Associate Professor at City University of New York and holds a DPhil (PhD) from the University of Oxford.